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Background: The relationship between anemia and outcomes after radiotherapy has not been systematically
addressed. The study aimed to assess the prevalence and prognostic value of anemia in patients receiving primary
radiotherapy for esophageal squamous cell carcinoma (ESCC).
Methods: A total of 103 patients with ESCC were retrospectively reviewed. Anemia was defined as a hemoglobin
level <12 g/dl for men and <11 g/dl for women. The 3-year and 5-year overall survival (OS) and disease-free survival
(DFS) were analyzed between the anemic and non-anemic groups using the Kaplan-Meier method and the Cox
proportional hazards model.
Results: No significant differences were observed in patient characteristics between the anemic and non-anemic
groups. The prevalence of anemia was 29.1%. The 3-year and the 5-year OS were 43% and 37%, respectively, in the
non-anemic group, and 20% and 17%, respectively, in the anemic group. The 3-year and the 5-year DFS were 37% and
26%, respectively, in the non-anemic group, and 13% and 10%, respectively, in the anemic group. Survival analysis using
the Kaplan-Meier method showed that there was significant difference between anemia and non-anemia (P < 0.02).
In a multivariate analysis, anemia was identified as a highly significant prognostic factor for 3-year OS (hazard ratio
1.916; P = 0.012) and 3-year DFS (hazard ratio 1.973; P = 0.007), independent of T stage and the status of lymph nodes,
and 5-year OS (hazard ratio 1.705; P = 0.027) and 5-year DFS (hazard ratio 1.980; P = 0.005), independent of TNM stage
and the status of lymph nodes.
Conclusions: Anemia before primary radiotherapy was associated with poor prognosis and an increased risk of relapse,
which may serve as a new prognostic factor for ESCC.
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Esophageal carcinoma is the eighth most common can-
cer and the sixth highest cancer risk for mortality in the
world [1]. There is a remarkable geographic variation
in esophageal cancer incidence [2]. China has a high
incidence of esophageal cancer, about 20 times higher
than that in low-incidence areas of Africa [3,4]. There are
two major histological types of esophageal carcinoma:* Correspondence: zhangfang820127@163.com
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unless otherwise stated.esophageal squamous cell carcinoma (ESCC) and adeno-
carcinoma. ESCC continues to be the major type of
esophageal cancer in China and other East Asian coun-
tries, whereas adenocarcinoma is more common in the
United States and European countries.
Anemia is known to be a common condition in cancer
patients, and about 30% of cancer patients suffer from
anemia [5,6]. Disorders of iron metabolism, blood mar-
row insufficiency or metastases, malnutrition, bleeding
at tumor site, catabolism of patients with tumor burden
and relative deficiency of erythropoietin all play a role
in anemic pathogenesis. Anemia was found to be anLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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lignant tumors and hematologic malignancies in a meta-
analysis [5]. Anemia is an indicator of poor prognosis in
T1-T2 squamous cell carcinoma of the glottic larynx [7].
In a series of 217 patients with squamous cell carcinomas
in the head and neck treated with curative radiation ther-
apy alone, Dubray and colleagues [8] found that the 2-year
local-regional control rate decreased and the relative risk
of death increased for anemia. Grigiene and colleagues [9]
analyzed the outcome of 162 patients with uterine cervical
carcinoma treated with irradiation and found that the
hemoglobin (Hb) level before treatment had a significant
influence on overall survival (OS), disease-free survival
(DFS) and local relapse-free survival.
However, little is known about the significance of anemia
in the outcome of ESCC patients undergoing primary
radiotherapy. The aim of this study was to evaluate the
prevalence and prognostic value of anemia in ESCC and
its relationship with other prognostic factors.
Methods
Patients
Between 1 January 2006 and 31 December 2007, 154 pa-





















Status of lymph nodes Negative
Positive
Values are shown as median (range) or number, as appropriate.Department of Radiation Oncology, Qilu Hospital of
Shandong University, Jinan, China, were enrolled in this
study. The exclusion criteria were patients with the non-
squamous cell subtype, patients without record of Hb, and
patients who died of complications of radiotherapy. Conse-
quently, 103 patients were available for the present study.
All non-surgical patients in this study were staged accord-
ing to routine practice with air contrast barium esophago-
graphy, upper gastrointestinal endoscopy with histological
biopsies and cervical, chest and abdominal contrast com-
puted tomography. All surgical patients were staged in ac-
cordance with the American Joint Committee on Cancer
TNM staging system [10]. All patients received radiother-
apy alone or post-operative radiotherapy or radiochemo-
therapy according to the practice. Radiotherapy was started
on day 1 and delivered at 2 Gy/day for 5 days a week for a
total radiation dose of 60-70 Gy for non-surgical patients,
and a total radiation dose of 50 Gy for surgical patients.
Definition of anemia
The definition of anemia used in this study was kept con-
sistent with the definitions used by our laboratory and
China-specific criteria: a Hb level of less than 12 g/dl for
men and less than 11 g/dl for women [11]. A patient wasanemic patient groups
Anemic Non-anemic P value
61 (41-82) 60 (45-83) 0.796
27:3 64:9 0.738
11.4 (8.6-11.9) 13.95 (12.0-15.8) 0.000
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teria before radiotherapy.
Follow-up
Follow-up data were collected until death or 31 December
2012. All patients had a regular follow-up schedule including
a complete history and physical examination every 3 months
during the first 2 years, every 6 months during the first 3
to 5 years and every year thereafter. Routine radiological
examinations were performed when necessary.
Statistical analysis
Differences in patient characteristics were assessed using
the Mann–Whitney test for continuous variables and the
χ2 test for categorical variables. Analysis and comparison
of survival curves were performed using Kaplan–Meier
curves and log-rank analysis. For the analysis of 3-year
and 5-year OS, events were defined as death from any
cause. For the analysis of 3-year and 5-year DFS, events
were defined as first loco-regional or distant tumor re-
lapse or death from any cause. The Cox proportional haz-
ards model was used to determine the hazard ratio (HR)
of variables on 3-year and 5-year OS and DFS in univari-
ate and multivariate analysis. The results were given asFigure 1 Kaplan-Meier curves for the survival of all 103 patients with
(a) and disease-free survival (b) between the non-anemic and anemic grou
disease-free survival (d) between the non-anemic and anemic groups wereHR with their 95% CI. All statistical tests were two-sided
and P < 0.05 was considered as significant. Data were ana-
lyzed using statistical package SPSS version 17.0 (SPSS
Inc., Chicago, IL, USA).Results
Characteristics of the patients
A total of 103 patients (91 men and 12 women) were retro-
spectively analyzed in this study. The median age of the pa-
tients was 60 years (range 41 to 83 years) at the date
diagnosed. The median follow-up time was 18 months
(range 3 to 87 months). There were no significant differ-
ences between non-anemic group and anemic group in age
(P = 0.796), gender (P = 0.738), tumor location (P = 0.548),
treatment modality (P = 0.519), TNM stage (P = 0.296), T
stage (P = 0.201) and the status of lymph nodes (P = 0.357).
Patient characteristics are presented in Table 1.The prevalence of anemia
Anemia was diagnosed in 27 (29.7%) men and three (25%)
women. There were 30 anemic patients in 103 patients.
The median Hb levels were 13.9 g/dl in the non-anemic
group and 11.3 g/dl in the anemic group. The prevalenceesophageal squamous cell carcinoma. Both 3-year overall survival
ps were statistically significant. Both 5-year overall survival (c) and
statistically significant.
Table 2 Cox univariate analysis for 3-year survival in 103 patients
3-Year overall survival 3-Year disease-free survival
HR 95% CI P HR 95% CI P
Hemoglobin (non-anemic vs anemic) 1.941 1.177-3.202 0.009 1.999 1.232-3.244 0.005
Tumor location (C vs U vs M vs L) 0.936 0.720-1.218 0.623 0.883 0.686-1.136 0.333
Treatment modality (RT vs S + RT vs CRT vs S + CRT) 0.795 0.615-1.027 0.079 0.874 0.697-1.096 0.244
TNM stage (I vs II vs III vs IV) 1.767 1.240-2.519 0.002 2.052 1.431-2.945 0.000
T stage (T1 vs T2 vs T3 vs T4) 1.409 1.017-1.952 0.039 1.543 1.125-2.116 0.007
Status of lymph node (negative vs positive) 2.676 1.582-4.527 0.000 2.241 1.376-3.652 0.001
C, cervical; CRT, chemoradiotherapy; HR, hazard ratio; L, low; M, middle; RT, radiotherapy; S, surgery; U, upper.
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was 29.1%.
Correlation of anemia with patient survival
The 3-year and 5-year OS were 43% and 37%, respect-
ively, in the non-anemic group, and were 20% and 17%,
respectively, in the anemic group. The 3-year and the 5-
year DFS were 37% and 26%, respectively, in the non-
anemic group, and 13% and 10%, respectively, in the
anemic group. The Kaplan-Meier method showed that
both 3-year and 5-year OS and DFS in the non-anemic
group were significantly better than those in the anemic
group (P < 0.05; Figure 1).
The Cox univariate model showed that anemia, the
status of lymph node, TNM stage and T stage were sig-
nificantly correlated to 3-year and 5-year OS and DFS.
The HRs for 3-year and 5-year OS with anemia were
1.941 (95% CI 1.177 to 3.202; P = 0.009) and 1.799 (95%
CI 1.123 to 2.882; P = 0.015), respectively. The HRs for
3-year and 5-year DFS with anemia were 1.999 (95% CI
1.232 to 3.244; P = 0.005) and 1.946 (95% CI 1.217 to
3.112; P = 0.005), respectively. Anemia before radiother-
apy was associated with poor prognosis and an increased
risk of relapse (Tables 2 and 3).
Using multivariate analysis, anemia was identified as a
significant prognostic factor for 3-year OS (HR 1.916; P =
0.012) and 3-year DFS (HR 1.973; P = 0.007), independent
of T stage and the status of lymph nodes, and for 5-yearTable 3 Cox univariate analysis for 5-year survival in 103 pat
5-Year overall s
HR 95
Hemoglobin (non-anemic vs anemic) 1.799 1.1
Tumor location (C vs U vs M vs L) 0.945 0.7
Treatment modality (RT vs S + RT vs CRT vs S + CRT) 0.856 0.6
TNM stage (I vs II vs III vs IV) 1.732 1.2
T stage (T1 vs T2 vs T3 vs T4) 1.319 0.9
Status of lymph node (negative vs positive) 2.216 1.3
C, cervical; CRT, chemoradiotherapy; HR, hazard ratio; L, low; M, middle; RT, radiotheOS (HR 1.705; P = 0.027) and 5-year DFS (HR 1.980; P =
0.005), independent of TNM stage and the status of lymph
nodes (Table 4 and 5).
Discussion
In the present study, the prevalence of anemia in patients
with ESCC undergoing primary radiotherapy was 29.1%,
consistent with the previously reported prevalence of
anemia in squamous cell carcinomas of the head and neck
(29%) [8]. Similarly, the prevalence of anemia was 35% in
rectal carcinoma patients undergoing neoadjuvant radio-
therapy, and 44% in advanced Ewing’s sarcoma patients
undergoing chemotherapy [12,13].
Recent studies showed that anemia was associated with
poor prognosis and an increased risk of relapse [14,15]. In
our recent study, we found that anemia was identified as a
highly significant prognostic factor for 2-year OS and
DFS, independent of TNM stage and initial treatment in
ESCC treated with primary radiotherapy [16]. In order to
investigate whether anemia would continue to affect sur-
vival, we analyzed patients between 1 January 2006 and 31
December 2007 and concluded similar results. In our
current study, we found that 3-year and 5-year OS were
43% and 37%, respectively, in the non-anemic group, and
20% and 17%, respectively, in the anemic group. More-
over, 3-year and 5-year DFS were 37% and 26%, respect-
ively, in the non-anemic group, and 13% and 10%,
respectively, in the anemic group. Both 3-year and 5-yearients
urvival 5-Year disease-free survival
% CI P HR 95% CI P
23-2.882 0.015 1.946 1.217-3.112 0.005
39-1.208 0.650 0.935 0.729-1.199 0.595
81-1.076 0.183 0.916 0.741-1.133 0.420
40-2.418 0.001 1.783 1.263-2.518 0.001
88-1.761 0.060 1.441 1.071-1.939 0.016
94-3.523 0.001 1.769 1.127-2.776 0.013
rapy; S, surgery; U, upper.
Table 4 Cox multivariate analysis for 3-year survival in 103 patients
3-Year overall survival 3-Year disease-free survival
HR 95% CI P HR 95% CI P
Hemoglobin (non-anemic vs anemic ) 1.916 1.155-3.180 0.012 1.973 1.204-3.233 0.007
T stage (T1 vs T2 vs T3 vs T4) 1.390 0.980-1.971 0.065 1.607 1.144-2.258 0.006
Status of lymph node (negative vs positive) 2.456 1.448-4.165 0.001 1.994 1.218-3.263 0.006
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better than those in the anemic group (P < 0.05). Similarly,
Zhao and colleagues [17] analyzed the effect of anemia on
survival in 303 patients with locally advanced esopha-
geal carcinoma undergoing irradiation and reported
that there was a statistically significant reduction in sur-
vival and loco-regional control rates.
Several hypotheses have been proposed to explain the
relationship between anemia and cancer [18-21]. First,
anemia is known to produce tumor hypoxia which has
oncogenic actions through the associated genomic in-
stability, mutagenesis and disordered cell growth [18,19].
Tumor hypoxia also confers radio-resistance through the
hypoxia-associated reduction in free-radical production
and consequent radiotherapy-induced DNA damage [20].
Moreover, tumor hypoxia is associated with a poor prog-
nosis in patients with advanced head and neck cancer [21].
Second, bulky tumors might have a more anemic condition
compared with small volume tumors. In patients with early
cervical cancer, the prevalence of pretreatment anemia was
12.3% which is a relatively lower incidence than that of
locally advanced cervical cancer reported in previous
studies (approximately 25%) [22-24]. Moreover, a re-
view article also reported that Hb levels prior to and dur-
ing radiotherapy in the patients with cervical cancer are
strongly correlated with tumor size (P < 0.001) [25]. It may
partially explain the prognostic impact on survival in pa-
tients with cervical cancer. Third, Barkati and colleagues
[26] reported that a lower Hb level was related to a more
infiltrative and aggressive disease, such as uterine corpus
invasion and nodal metastases, in 263 patients with locally
advanced cervical cancer.
In the present study, the prevalence of anemia was
31.4% in I and II stage patients, and 26.9% in III and IV
stage patients. The prevalence of anemia was 36.4% in
T1 and T2 stage patients, and 25.7% in T3 and T4 stage
patients. The results did not show that the patients withTable 5 Cox multivariate analysis for 5-year survival in 103 p
5-Year overall surviva
HR 95% CI
Hemoglobin (non-anemic vs anemic ) 1.705 1.063-2.7
TNM stage (I vs II vs III vs IV) 1.428 0.986-2.0
Status of lymph node (negative vs positive) 1.738 1.051-2.8stages III and IV, and T3 and T4 might have a more
anemic condition than the patients with stages I and II,
and T1 and T2; however, the proportion of anemia in
patients without lymph nodes metastases was 24.4%,
which is a relatively lower incidence than that of patients
with lymph nodes metastases ( 32.8%). The results sug-
gested that patients with lymph nodes metastases might
have a more anemic condition compared with patients
without lymph nodes metastases, and this is one possible
explanation for poor survival and anemia in ESCC.
Overall, it is clear that the anemic group has an inferior
prognosis in the study, but the underlying mechanisms
remain unknown. Further research is needed to detect
the mechanisms.
Many prognostic factors have been found for esopha-
geal cancer, such as the status of lymph nodes, TNM
stage, tumor location, and T stage. All these factors have
been included in our analysis. In this study, we found
that the status of lymph node, TNM stage and T stage
were significantly correlated to 3-year OS and 3-year
DFS by univariate analysis. Using multivariate analysis,
the status of lymph node was an independent prognos-
tic factor for 3-year OS, while the status of lymph node
and T stage were independent prognostic factors for 3-
year DFS. Furthermore, we found that the status of lymph
node and T stage were significantly correlated to 5-year
OS by univariate analysis, and the status of lymph node
was an independent prognostic factor by multivariate ana-
lysis. For 5-year DFS, the status of lymph node, TNM
stage and T stage were independent prognostic factors by
univariate analysis, and TNM stage was an independent
prognostic factor by multivariate analysis. Our results are
similar to those of previous studies [17,27,28].
In present study there are several limitations. First, we
did not account for the possible correction of anemia
before primary radiotherapy; blood transfusion and ad-
ministration of erythropoietin in cancer patients mayatients
l 5-Year disease-free survival
P HR 95% CI P
37 0.027 1.980 1.232-3.180 0.005
69 0.060 1.771 1.265-2.479 0.001
75 0.031 1.304 0.724-2.347 0.377
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treatments such as surgery and chemotherapy partially
contribute to the anemic condition before radiotherapy
in patients with ESCC. Third, anemia before primary
radiotherapy could be frequently associated with symp-
toms such as malnutrition and bleeding at the tumor site
as the blood test was performed. As ours was a retrospect-
ive study, we could not consider these confounding factors
or the comorbid conditions of the patients, which may
affect our results. Hence, it is difficult to judge anemia
as a direct or indirect prognostic factor for poor sur-
vival; however, it is clear that the anemic group has a
shorter survival. Further research with larger sample sizes
is needed to validate these findings.
Conclusion
Our findings indicate that anemia before primary radio-
therapy is a new prognostic factor for ESCC, independent
of other prognostic factors. Hb is a routine examination
and thus anemia can be easily assessed to provide a pre-
diction for the prognosis of ESCC patients.
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